Christine Schmid-Tannwald
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroendocrine Tumors | 13 | 2026 | 157 | 5.550 |
Why?
|
| Liver Neoplasms | 13 | 2024 | 831 | 4.340 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 18 | 2024 | 304 | 3.310 |
Why?
|
| Positron Emission Tomography Computed Tomography | 10 | 2025 | 107 | 2.060 |
Why?
|
| Pancreatic Neoplasms | 6 | 2026 | 769 | 1.850 |
Why?
|
| Organometallic Compounds | 5 | 2025 | 142 | 1.560 |
Why?
|
| Contrast Media | 12 | 2023 | 1011 | 1.290 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2024 | 3605 | 1.220 |
Why?
|
| Brachytherapy | 3 | 2024 | 139 | 0.950 |
Why?
|
| Positron-Emission Tomography | 10 | 2026 | 354 | 0.900 |
Why?
|
| Everolimus | 1 | 2024 | 35 | 0.830 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2023 | 11 | 0.810 |
Why?
|
| Capecitabine | 1 | 2024 | 103 | 0.800 |
Why?
|
| Retrospective Studies | 27 | 2026 | 10972 | 0.790 |
Why?
|
| Colorectal Neoplasms | 3 | 2024 | 1103 | 0.780 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2023 | 677 | 0.770 |
Why?
|
| Gadolinium DTPA | 8 | 2015 | 239 | 0.710 |
Why?
|
| Liver Diseases | 2 | 2013 | 249 | 0.650 |
Why?
|
| Diagnostic Imaging | 3 | 2023 | 467 | 0.640 |
Why?
|
| Liver | 3 | 2014 | 1231 | 0.630 |
Why?
|
| Image Enhancement | 5 | 2015 | 503 | 0.600 |
Why?
|
| Tyrosine | 6 | 2016 | 135 | 0.590 |
Why?
|
| Receptors, Somatostatin | 5 | 2026 | 36 | 0.580 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 320 | 0.540 |
Why?
|
| Middle Aged | 31 | 2026 | 29427 | 0.520 |
Why?
|
| Humans | 48 | 2026 | 98076 | 0.500 |
Why?
|
| Octreotide | 3 | 2026 | 32 | 0.490 |
Why?
|
| Crohn Disease | 1 | 2023 | 844 | 0.480 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2023 | 450 | 0.460 |
Why?
|
| Ki-67 Antigen | 3 | 2025 | 70 | 0.460 |
Why?
|
| Male | 34 | 2026 | 47075 | 0.450 |
Why?
|
| Aged | 22 | 2026 | 21758 | 0.450 |
Why?
|
| Intestinal Neoplasms | 2 | 2026 | 77 | 0.440 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 356 | 0.420 |
Why?
|
| Liver Abscess | 1 | 2014 | 10 | 0.410 |
Why?
|
| Radiopharmaceuticals | 5 | 2026 | 217 | 0.410 |
Why?
|
| Adult | 24 | 2026 | 29538 | 0.400 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 112 | 0.400 |
Why?
|
| Diagnosis, Differential | 7 | 2016 | 1567 | 0.380 |
Why?
|
| Female | 30 | 2026 | 51535 | 0.380 |
Why?
|
| Stomach Neoplasms | 2 | 2026 | 319 | 0.370 |
Why?
|
| Reproducibility of Results | 10 | 2024 | 2783 | 0.360 |
Why?
|
| Radiosurgery | 2 | 2016 | 351 | 0.350 |
Why?
|
| Fistula | 1 | 2011 | 44 | 0.340 |
Why?
|
| Treatment Outcome | 7 | 2024 | 9711 | 0.310 |
Why?
|
| Sensitivity and Specificity | 9 | 2023 | 1945 | 0.310 |
Why?
|
| Brain Neoplasms | 4 | 2016 | 839 | 0.300 |
Why?
|
| Observer Variation | 5 | 2015 | 579 | 0.300 |
Why?
|
| Glioma | 3 | 2016 | 309 | 0.280 |
Why?
|
| Intestine, Small | 2 | 2023 | 318 | 0.270 |
Why?
|
| Prostatic Neoplasms | 5 | 2023 | 1836 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2024 | 2666 | 0.250 |
Why?
|
| Gallium Radioisotopes | 2 | 2023 | 18 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 1535 | 0.250 |
Why?
|
| Biomarkers, Tumor | 2 | 2026 | 1764 | 0.250 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 7389 | 0.240 |
Why?
|
| Prognosis | 5 | 2026 | 4116 | 0.230 |
Why?
|
| Intestines | 2 | 2023 | 441 | 0.230 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2025 | 9 | 0.230 |
Why?
|
| Paraganglioma | 1 | 2025 | 15 | 0.220 |
Why?
|
| Pheochromocytoma | 1 | 2025 | 53 | 0.220 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2025 | 84 | 0.210 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2024 | 80 | 0.200 |
Why?
|
| Intestine, Large | 1 | 2023 | 15 | 0.200 |
Why?
|
| Pacemaker, Artificial | 1 | 2024 | 119 | 0.200 |
Why?
|
| Abdomen | 3 | 2013 | 120 | 0.200 |
Why?
|
| Multimodal Imaging | 1 | 2024 | 116 | 0.190 |
Why?
|
| Gadolinium | 2 | 2013 | 95 | 0.190 |
Why?
|
| AIDS Dementia Complex | 1 | 2022 | 7 | 0.180 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 271 | 0.180 |
Why?
|
| ROC Curve | 5 | 2016 | 794 | 0.180 |
Why?
|
| Electrocardiography | 1 | 2024 | 527 | 0.180 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2015 | 642 | 0.170 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 1 | 2020 | 3 | 0.160 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2020 | 11 | 0.160 |
Why?
|
| Forensic Medicine | 1 | 2020 | 7 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2025 | 503 | 0.160 |
Why?
|
| Hyoid Bone | 1 | 2020 | 14 | 0.160 |
Why?
|
| Larynx | 1 | 2020 | 36 | 0.150 |
Why?
|
| Dementia | 1 | 2022 | 226 | 0.150 |
Why?
|
| Multidetector Computed Tomography | 1 | 2020 | 57 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2021 | 801 | 0.140 |
Why?
|
| Fractures, Bone | 1 | 2020 | 161 | 0.140 |
Why?
|
| Reference Standards | 2 | 2015 | 146 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 1302 | 0.120 |
Why?
|
| Diverticulitis | 1 | 2015 | 9 | 0.120 |
Why?
|
| Subtraction Technique | 1 | 2016 | 126 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2016 | 73 | 0.110 |
Why?
|
| Diverticulum | 1 | 2015 | 45 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 2373 | 0.110 |
Why?
|
| Astrocytoma | 1 | 2015 | 85 | 0.110 |
Why?
|
| Acute Disease | 1 | 2016 | 860 | 0.100 |
Why?
|
| Exudates and Transudates | 1 | 2014 | 13 | 0.100 |
Why?
|
| Patient Positioning | 1 | 2015 | 70 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 2658 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2014 | 333 | 0.100 |
Why?
|
| Meglumine | 1 | 2013 | 36 | 0.100 |
Why?
|
| Astrocytes | 1 | 2013 | 142 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2016 | 984 | 0.100 |
Why?
|
| Seminal Vesicles | 1 | 2013 | 40 | 0.100 |
Why?
|
| Young Adult | 6 | 2025 | 7507 | 0.090 |
Why?
|
| Biopsy | 2 | 2013 | 1224 | 0.090 |
Why?
|
| HIV Infections | 1 | 2022 | 1018 | 0.090 |
Why?
|
| Pregnancy, Ectopic | 1 | 2012 | 37 | 0.090 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 212 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 302 | 0.090 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2012 | 126 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2014 | 977 | 0.090 |
Why?
|
| Intestinal Fistula | 1 | 2011 | 32 | 0.090 |
Why?
|
| Fibrosis | 1 | 2013 | 234 | 0.090 |
Why?
|
| Abdominal Abscess | 1 | 2011 | 24 | 0.090 |
Why?
|
| Kidney | 2 | 2015 | 1123 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 155 | 0.080 |
Why?
|
| Pancreas | 1 | 2013 | 269 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 288 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 384 | 0.080 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 337 | 0.080 |
Why?
|
| Patient Safety | 1 | 2013 | 235 | 0.080 |
Why?
|
| Sickness Impact Profile | 1 | 2009 | 29 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2013 | 673 | 0.080 |
Why?
|
| Vision, Ocular | 1 | 2009 | 73 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 556 | 0.070 |
Why?
|
| Eye Diseases | 1 | 2009 | 58 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2013 | 601 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 2080 | 0.070 |
Why?
|
| Adolescent | 4 | 2020 | 10079 | 0.070 |
Why?
|
| Time Factors | 2 | 2014 | 5567 | 0.070 |
Why?
|
| Robotic Surgical Procedures | 1 | 2014 | 411 | 0.070 |
Why?
|
| Lutetium | 1 | 2025 | 4 | 0.060 |
Why?
|
| Algorithms | 1 | 2014 | 2002 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 1782 | 0.060 |
Why?
|
| Biological Transport | 2 | 2016 | 401 | 0.050 |
Why?
|
| Prostatectomy | 3 | 2013 | 490 | 0.050 |
Why?
|
| Femoral Artery | 1 | 2024 | 96 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 422 | 0.050 |
Why?
|
| Radiologists | 1 | 2023 | 59 | 0.050 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 156 | 0.050 |
Why?
|
| Kinetics | 2 | 2015 | 1476 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2023 | 183 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 146 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2022 | 40 | 0.040 |
Why?
|
| Quality of Life | 1 | 2009 | 1895 | 0.040 |
Why?
|
| Genotype | 1 | 2025 | 1888 | 0.040 |
Why?
|
| Adrenalectomy | 1 | 2020 | 41 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2020 | 117 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 523 | 0.040 |
Why?
|
| Autopsy | 1 | 2020 | 131 | 0.040 |
Why?
|
| Pregnancy | 2 | 2020 | 3244 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 278 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 945 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 1254 | 0.030 |
Why?
|
| Neoplasms | 1 | 2013 | 3334 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 59 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2016 | 86 | 0.030 |
Why?
|
| Whole Body Imaging | 1 | 2015 | 40 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 370 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2681 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 64 | 0.020 |
Why?
|
| Pregnancy, Heterotopic | 1 | 2012 | 3 | 0.020 |
Why?
|
| Pregnancy, Abdominal | 1 | 2012 | 5 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 3212 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2012 | 49 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 660 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 340 | 0.020 |
Why?
|
| Cicatrix | 1 | 2012 | 78 | 0.020 |
Why?
|
| Rectum | 1 | 2013 | 150 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 291 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2012 | 162 | 0.020 |
Why?
|
| Ascites | 1 | 2011 | 55 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 1193 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 582 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 4823 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 720 | 0.020 |
Why?
|
| National Eye Institute (U.S.) | 1 | 2009 | 1 | 0.020 |
Why?
|
| Germany | 1 | 2009 | 84 | 0.020 |
Why?
|
| Population Groups | 1 | 2009 | 44 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1610 | 0.020 |
Why?
|
| Child | 1 | 2020 | 7681 | 0.020 |
Why?
|
| Prevalence | 1 | 2009 | 1384 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 2036 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 3021 | 0.010 |
Why?
|
| United States | 1 | 2009 | 8196 | 0.010 |
Why?
|